ASPC 2018 Congress on CVD Prevention
Avatar

PCSK9 Inhibitors Today - When, How, and In Whom

By ASPC 2018 Congress on CVD Prevention FEATURING Jennifer Robinson
August 10, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

08:56
Janssen

The Importance of Returning to In-Person Care for Patients with Pulm…

Feat. R. Benza

Featured Video

23:07
Novo Nordisk – GLP-1 RA Therapy

Examining Clinical Trial Data on GLP-1 RAs and Basal Insulin in T2D:…

Feat. L. Coco, J. R. Gavin III

Related Content

AUTOPLAY
11:10
Craig Beavers

PCSK9 Inhibitors: Pharmacology, Indications, Drug Interactions, Dosi…

12:11
Peter Howard Jones

Clinical Trials with PCSK9 Inhibitors and Lipid Efficacy

12:04
Stephen Kopecky

Role of PCSK9 Inhibitors in Diabetes

16:49
Craig Beavers

Reducing LDL with PCSK9 Inhibitors: Current Controversies Discussion

33:20
Cardiology Fiesta 2016

PCSK9 Inhibitors in Clinical Practice

Feat. M. Davidson
10:18
Cleveland Clinic Heart, Vascular and Thoracic Institute

Results of the GLAGOV Trial: Global Assessment of Plaque Regression …

Feat. S. Nissen
03:04
Cleveland Clinic Heart, Vascular and Thoracic Institute

PCSK9 News from ACC: Recap of FOURIER, EBBINGHAUS substudy, SPIRE &a…

Feat. S. Nissen
28:39
Cardiovascular Disease Management - 4th Annual Symposium

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatme…

25:52
Cardiovascular Disease Management - 4th Annual Symposium

The Nation’s #1 Health Problem: Setting the Stage - Panel Discussion…

17:40
Cardiovascular Disease Management - 4th Annual Symposium

Can We Cure Arteriosclerosis? New Thoughts and Concepts and New Game…

31:39
Cardiovascular Disease Management - 4th Annual Symposium

Diabetes: An Epidemic - Panel Discussion / Q & A

Feat. R. Heuser, G. Adams
10:34
Scottsdale Interventional Forum 2017

PCI Pharmacology in 2017: Understanding the Essentials

Feat. M. Kutcher
25:42
Innovations in Cardiovascular Therapeutics 2016

PCSK9 inhibitors in U.S. practice 1 year later: Patient selection, c…

11:55
Michael Shapiro

Current Challenges in Lipid Lowering Therapy and Prevention of ASCVD

16:05
Seth Martin

Science of PCSK9 and LDL-C Lowering Efficacy

18:24
Stephen Kopecky

CV Outcomes Trials with PCSK9 Inhibitors – SPIRE, ODYSSEY, FOURIER a…

13:46
Seth Baum

Barriers to Accessing PCSK9 Inhibitors

16:13
Michael Shapiro

Update on PCSK9 Inhibitors Discussion

08:14
New Cardiovascular Horizons (NCVH) 2017

Role of Statins and PCSK9 Inhibitors

Feat. C. Walker
20:01
Savitha Subramanian

Utility of PCSK9 Inhibitors in LDL-C Lowering